(elderly subjects) and Bianchi and Stenier 5 showed that flumazenil speeds recovery. These studies, however, included a heavy premedieation with oral or intramuscular midazolam. Rubin and Rocke 6 also included a heavy premedication with midazolam, but found that spontaneous recovery occurred so rapidly that flumazenil would rarely be needed.
Four studies have examined the use of flumazenil for reversal of midazolam sedation without premeditation. Rodrigo et al. 7 found that a fixed dose, 0.5 nag, of flumazenil, given after short, 15 min, dental procedures markedly reduced the time for recovery from midazolam, average dose 6. The aim of this double-bfind, randomized placebocontrolled study was to re-assess the efficacy of flumazenil in reversing the effects of midazolam used for sedation during regional anaesthesia. We have used three measures of recovery: (1) antagonist. Instead, flumazenil was titrated to a maximum of one mg.
Methods

Patients
Twenty-four ASA I-II patients, four women, aged 18-55 yr, and scheduled to undergo peripheral surgery under regional anaesthesia, were consecutively enroled after approval by the Ethics Committee. Each patient gave written consent. Patients with any of the following were excluded: pregnancy, benzodiazepine allergy, recent (two weeks) or long-term benzodiazepine use, epilepsy, excessive consumption of alcohol, > four drinks per week, or caffeine, >_ four cups of coffee daily. The patients were randomly allocated to either flumazenil, 12 patients, or placebo 12 patients, in a double-blind manner. One patient from the flumazenil group could not complete the assessments in the Recovery Room, because the epidural block was too high and caused arm weakness. The patient was excluded from analysis and replaced by another patient. There were, therefore, 12 patients in each group.
Assessment of sedation
All procedures were explained to the patient in detail. Ample time was available for practice before baseline recordings. The patients were always assessed in a semireclining position. The Modified Steward Coma Scale (MSCS), adapted from reference 11, is described in Table  I .
TRIEGER TEST The Trieger Test J2 is an adaptation of the Bender-Gestalt test. ~7 For the Trieger Test, the subject is shown a simple design made of dots 9-10 mm apart and is asked to join the dots with a pencil. The performance is assessed by counting the number of dots missed and by measuring the total distance between the missed dots and the line drawn by the patient. The time taken to complete the task is also recorded. Patients with refractive error wore their spectacles for all assessments.
CRITICAL FLICKER FREQUENCY (CFF)
The CFF is the threshold frequency at which a flashing light is perceived to be constant. It provides a simple, quantitative and sensitive measure of central nervous system impairment. ~3-~6 It was measured using a custombuilt signal generator, incorporating goggles with a builtin light emitting diode, which presented a flickering red light (diameter = 4 mm) (wavelength 660 nm) to the patient's dominant eye. The other eye was occluded with an opaque goggle. The mean luminous intensity was 2.6 millicandelae (mcd) for all tests. To produce flicker, instantaneous luminous intensity oscillated between 0 and 5.2 mcd (mean intensity + 100%) according to a sinusoidal waveform. The CFF was assessed with the method of limits. (Although the method of forced choice is preferable in principle is both methods yield comparable resuits. The present work was done before the work described in reference 18.) For each trial, the flicker frequency (number of cycles per second) was initially 50 Hz and decreased at the rate of 1.3 Hz. see -l to 30 Hz. The patients were asked to press a hand-held button as soon as they perceived flicker. The frequency at which this occurred was recorded, and the procedure was repeated at least three times for each assessment. The average of these measures was used for scoring. When the patient failed to perform the test because of excessive sedation, a score of 30 Hz was arbitrarily assigned. This was necessary because even a single missing value results in exclusion of the patient in a repeated measures design. Pilot tests showed that 30 Hz was the lowest value that could be reliably measured in heavily sedated patients.
Because drugs often change pupillary diameter (and secondarily retinal illuminance, which influences CFF, 14) the pupillary diameter was measured before determination of the CFF, and analysis of covariance was used to determine whether or not changes in pupillary diameter could account for the CFF changes. When the block was established, midazolam, 30 ~g. kg -l was given/v. Increments of midazolam of 7.5 ~g. kg -~ were administered as needed at two-minute intervals, until the patient was sleepy but easily arousable with verbal commands (Level 2 on the sedation score of Table II ). This level of sedation was maintained until completion of the surgical procedure, by increments of midazolam of 7.5 ~tg. kg -l. At the end of surgery the MSCS was recorded, and the patient, still on the opelating table, was tilted to the semi-sitting position before performing the CFF and Trieger tests. These were the "pre-study drug" or time 0 assessments. Flumazenil, 0.1 mg. ml -l, or placebo, both supplied by Hoffmann-LaRoche, was administered at the rate of 2 ml initially over 20 see, followed by 20 see of observation and assignment of a sedation score. Further doses of 1 ml were given at each minute, until the patient was awake but not tense, sedation Score 4 on Table II, or until 10 ml of solution had been given. Ten minutes after the beginning of the study drug administration, the MSCS was recorded, and the patients performed the CFF and Trieger tests. The patient was then moved to a quiet recovery area, where normal nursing care was provided. The MSCS, CFF and Trieger tests were recorded every 30 min until three hours after the commencement of the administration of flumazenil or placebo, time 0. Patients were then discharged home or to the ward. All scoring was done by the same person.
Pain was controlled in the Recovery Room area by epidural injections of bupivacaine, 0.25%. The Recovery Room staff was informed about the study and was asked to inform us about any symptoms or problems. The patients were seen or contacted by telephone 24-hr postoperatively to inquire about pain at the injection site.
Anaesthesia and procedures
The patients were not premedicated. Baseline measures of the MSCS, CFF and Trieger tests were obtained 30 rain before entering the operating room. After insertion of a large bore /v cannula, the ECG electrodes, blood pressure cuff and pulse oximeter probes were attached. Epidural anaesthesia, using an indwelling catheter, was Statistics All procedures 19 were performed by J.C. Baskerville, and L.W Stitt, of Statlab (University of Western Ontario, London, Ontario). For each outcome variable, the change from the pre-study drug assessment (time 0) was calculated. The measures were thereby automatically adjusted for possible differences in baseline levels between fluma-
Flumazenil
Placebo lO
Number of men-women 10-2 10-2 0 Age (yr) 40.7 (6.9) 30.4 (7.1)* Height (em)
174 (9) zenil and placebo groups. Analysis of variance (ANOVAs) for repeated measures were used to assess the effect of drug (flumazenil versus placebo), time (repeated factor, seven assessments) and time-drug interaction. Greenhouse-Geisser adjustment of the significance levels were used. The level for significance was P < 0.05 for the ANOVAs. T tests, based on the pooled estimate of variance, derived from the ANOVAs, were used to compare flumazenil versus placebo at each assessment, t = 10, 30, 60, 90, 120, 150 and 180 rnin after study drug administration. The level of significance was P < 0.007 for the pooled t tests, in order to obtain an overall error rate of 0.05 (Bonferonni correction). Analysis of covariance was used to examine (1) the effect of the age difference between the flumazenil and placebo group; (2) the contribution of pupillary size to CFF changes. Unpaired t tests were used to compare the characteristics of the flumazenil versus placebo group. Level of significance was P < 0.05 for these t tests.
Results
Demographic data, duration of surgery and doses of midazolam and study drug are given in Table IlL There was an age difference between the flumazenil and plaeebo groups (P < 0.01). To investigate the effect of this imbalance, all comparisons between flumazenil and placebo were performed both with and without age as a covariate. Because age never had any noticeable effect, the results of the analysis without age as a covariate are given. For the other variables, the difference between the flumazenil and placebo groups did not approach significance.
Modified Stewart coma scale (MSCS)
There was a slightly greater increase for the flumazenil group at ten and 30 min after treatment (Figure 1 ). The differences did not reach significance (P < 0.03 and P < 0.08 respectively). The ANOVA yielded no significant effects.
Trieger dot test -number o f dots missed
Patients in the flumazenil group missed more dots than those in the placebo group from 30 to 180 min atter treatment ( Figure 2 ). The greatest differences occurred between 90 and 150 min after treatment and nearly reached significance (P ranged from 0.01 to 0.05). The ANOVA yielded drug (P < 0.04) and time (P < 0,001) effects without significant interaction.
Trieger dot test -total deviations f r o m dots
The total deviation from the dots was larger for patients in the flumazenil group from 30 to 180 min after treatment (Figure 3 ), but the differences did not reach significance. The ANOVA yielded a time effect (P < 0.001) but no drug effect or interaction.
Trieger dot test -completion times
Patients who had received flumazenil were faster than the placebo group from ten to 120 min after treatment ( Figure 4) . To investigate the effect of this difference, the completion time was entered as a time-varying covariate for both the number of dots missed and the total deviation from dots. There was a negative correlation (P < 0.001) between completion times and the number of dots missed, but the effects of drug and time, noted above, remained significant. There was also a similar negative correlation (P < 0.001) between completion times and total deviation from dots. The effect of time, noted above, remained significant.
Critical flicker frequency
Patients in the flumazenil group showed a higher frequency than the placebo group at ten minutes after treatment (P < 0.005) ( Figure 5 ). The differences between the two groups from 30 to 180 min after treatment did not approach significance. The ANOVA yielded no drug effect but there was an effect of time (P < 0.01). There was an interaction (P < 0.01) between drug and time, indicating that the pattern of CFF increase following study drug administration was different between flumazenil and placebo. Mean pupillary diameter was larger for the placebo group at baseline (pre-op) and during all subsequent measures except time 0, when there was no difference (Figure 6 ). Using pupil size as a time-varying covariate revealed no effect of pupillary diameter on the analysis of the CFF results.
Adverse events
Five patients experienced adverse events in the three hours following administration of the study drug. They all belonged to the placebo group. One patient had syncope upon standing up at three hours, two patients complained of transient di77iness, one patient was transiently confused, and one patient had hiccoughs. Syncope was treated with atropine, 0.4 mg/v. The other adverse events resolved rapidly without treatment. At the 24 hr assessment, one patient from the flumazenil group complained of mild to moderate pain at the injection site. No patients from the placebo group complained of pain at the injection site.
Discussion
The Critical Flicker Frequency results at ten minutes provided the only evidence that recovery was faster in the flumazenil group. The Modified Steward Coma Scale also revealed a faster recovery in the flumazenil group at ten minutes, but the difference was small and did not reach significance. By contrast, the Trieger Test (number of dots missed) revealed a better performance in the placebo group from 30 to 180 min after treatment. The differences nearly reached significance between 90 and 150 rain after treatment. A possible explanation for this unexpected finding is that patients of the flumazenil group were more alert and had better memory. They would accordingly have become bored with the highly repetitive Trieger Test.
The average dose of midazolam in the present study is slightly higher than that of the Kestin et al. l0 study but slightly smaller than that of the US multicentre study. 9 The average dose of flumazenil given in the present study (0.55 mg) is almost the same as the fLxed dose of 0.5 mg used by Kestin et al. zo but is less than the average dose reported in the US Multicenter Study, 0.72 mg. 9 The duration of surgery is almost the same for the three studies. Like Kestin et al., we could only demonstrate a weak and transient reversal of midazolam effects by flumazenil, presumably because of the rapid spontaneous recovery from midazolam.
The US multicentre study 9 demonstrated a clear effect of flumazenil for 60 min whereas our results revealed only a weak and transient effect. A possible explanation is that, at the end of surgery, the patients of the US Study were more heavily sedated than were our patients. The mean Observer's Assessment of Alertness/Sedation Scale (OAA/S) ~~ was 3 in the US Study, indicating that the patients responded only to loud or repeated verbal commands, or had slurred speed or marked jaw relaxation or marked palpebral ptosis. The intended level of sedation in our study was to keep the patient sleepy yet easily arousable verbally (probably corresponding to an OAA/S score of 2). The sedative end point is not specified in the US multicentre study.
Our results cannot be compared with those of Rodrigo et al. 7 because there is a three-fold difference in the duration of surgery (45 min vs 15 min). Likewise, it is difficult to compare our results with those of Ochs et al.S because they used a much larger dose of midazolam.
The small, transient effect of flumazenil observed in the present study cannot be explained by lack of sensitivity of the measures used to assess recovery. Critical Flicker Frequency test is so sensitive that neither the placebo nor the flumazenil group had returned to baseline after three hours ( Figure 5 ). We conclude that flumazenil is rarely needed when midazolam is titrated to provide light sedation during regional anaesthesia. The spontaneous recovery from midazolam is fast enough.
